Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The Nucleic Acid Therapeutics CDMO market encompasses contract service providers that support the end-to-end development and manufacturing of oligonucleotide-based medicines, including mRNA therapeutics, siRNA, antisense oligonucleotides, plasmid DNA, and gene therapy vectors. Valued at approximately $4.92 billion in 2025, the market is positioned to grow at a 16.2% annual rate, substantially outpacing the broader CDMO sector, reflecting the accelerating clinical and commercial momentum behind nucleic acid modalities. This growth trajectory is further supported by the fact that the overall global CDMO market reached over $150 billion in 2024, with nucleic acid therapeutics representing one of its most dynamic and high-value subsectors.

• •Market valued at ~$4.92 billion in 2025, with an estimated ~$5.64 billion in 2026
• •Projected 16.2% CAGR through 2033, significantly outpacing the broader CDMO market
• •Covers mRNA therapeutics, siRNA, antisense oligonucleotides, plasmid DNA, and gene therapy vectors

The primary engine of growth is the expanding clinical pipeline of nucleic acid-based therapeutics across infectious disease, oncology, rare genetic disorders, and protein replacement indications. Advancements in delivery technologies, most notably lipid nanoparticle (LNP) formulations, have dramatically improved the therapeutic viability of oligonucleotide drugs, increasing demand for specialized manufacturing capacity. Additional catalysts include regulatory approvals that have validated the commercial feasibility of nucleic acid modalities, rising biotech startup activity outsourcing development work rather than building internal infrastructure, and sustained investment in mRNA platform technologies that enable rapid adaptation to new disease targets.

• •Expanding clinical pipeline across infectious diseases, oncology, rare genetic disorders, and metabolic conditions
• •Breakthroughs in lipid nanoparticle and other delivery technologies driving commercial-scale manufacturing demand
• •Regulatory approvals validating nucleic acid modalities, combined with biotech sector preference for outsourced development over in-house manufacturing

The market is commonly segmented by modality type, encompassing mRNA therapeutics, siRNA, antisense oligonucleotides, plasmid DNA, and gene therapy vectors, as well as by application area, including infectious disease vaccines, cancer immunotherapies, protein replacement therapies, and metabolic disorder treatments. North America, particularly the United States with an estimated market size of approximately $1.43 billion in 2024, commands the largest regional share due to the concentration of biotechnology innovation, clinical trial activity, and regulatory expertise. Europe follows as the second-largest region, benefiting from strong academic research infrastructure and established pharmaceutical manufacturing clusters, while the Asia-Pacific region is emerging as a fast-growing alternative offering competitive manufacturing costs and rapidly expanding capacity.

• •U.S. market alone estimated at ~$1.43 billion in 2024, representing a significant share of the global market
• •Segmented by modality (mRNA, siRNA, AONs, pDNA, gene therapy) and application (infectious diseases, oncology, metabolic disorders, rare diseases)
• •Asia-Pacific is the fastest-growing regional market, driven by expanding manufacturing infrastructure and cost-competitive capacity

Who are the notable companies in the industry?

The competitive structure of the Nucleic Acid Therapeutics CDMO market features a mix of large, fully integrated contract development and manufacturing organizations that offer end-to-end services across multiple modalities, and smaller, more specialized providers that focus on specific technologies such as in vitro transcription, oligonucleotide synthesis, or lipid nanoparticle formulation. The industry remains moderately fragmented, with no single provider dominating the full value chain, though certain large integrated operators have broader geographic footprints and cross-modality capabilities. The principal manufacturing process routes include plasmid DNA upstream production, in vitro transcription for mRNA synthesis, and complex formulation and fill-finish operations, with capacity concentrated primarily in North America and Western Europe, complemented by growing facilities in select Asia-Pacific locations and European hubs such as Ireland.

• •Competitive structure includes large integrated CDMOs offering end-to-end services alongside smaller specialty firms focused on specific technologies or modalities
• •Primary manufacturing process routes: plasmid DNA fermentation, in vitro transcription for mRNA, oligonucleotide chemical synthesis, and lipid nanoparticle formulation
• •Manufacturing capacity concentrated in North America and Western Europe, with growing presence in Asia-Pacific and European regulatory-hub locations

What are the recent trends and outlook?

The market outlook remains strongly positive, with the projected doubling and tripling of market value by the early 2030s reflecting both increased adoption of nucleic acid therapeutics and continued expansion of contract manufacturing capacity. Key trends include growing investment in continuous manufacturing and process intensification technologies to improve yield and reduce costs, heightened focus on supply chain resilience following the lessons of the global pandemic era, and increasing demand for multimodal CDMO partners capable of supporting both clinical-stage development and commercial-scale production under stringent quality frameworks. The next phase of market evolution is expected to see tighter integration between process development, analytical characterization, and manufacturing services as developers seek partners who can accelerate path-to-clinic and path-to-market timelines.

• •Projected market value approaching $15 billion by 2033, driven by sustained biotech investment and expanding approved product portfolios
• •Growing emphasis on continuous manufacturing, process intensification, and supply chain resilience across the CDMO sector
• •Increasing demand for integrated multimodal partners capable of supporting programs from preclinical development through commercial launch